Yesterday Julien Cicero defended his PhD thesis in OncoLille Institute, about the role of neurotrophins and related receptors in brain metastasis of triple negative breast cancer. What a great thesis defense, we enjoyed a lot his very clear presentation and his responses to the questions of the committee. Perfect time Read more…
In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…
We are happy to share that Nathalie Maubon, PhD, our CEO/CSO is currently attending BioAsia Taiwan, organized in Taipei. The event aims at building on the success of recent years’ gatherings to bring together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia, and explore business opportunities Read more…
Julien Cicero, with whom we are collaborating about the study of breast cancer metastasis mechanisms, was proud to present his PhD work during the last EACR conference. It was held in Torino (Italy) last month, during which Julien could discuss with cancer researchers from all around the world. His poster Read more…
Last week, we had the pleasure to participate in the conference about Alternatives to Animal Experimentation which was held last week in Biocitech park, Romainville, France. It was organized by Adebiotech think tank, and gathered researchers from private companies and academia, and also people from organizations like FC3R and PETA Read more…
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…
We are glad starting a new Year! But nothing better than assessing what happened along the last one to glance back at the road traveled so far… and looking forward to what’s next!
End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free validation of drugs, but it requires the design of a relevant and more predictive drug Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
We were glad to participate in FIE (Food Ingredients Europe) fair, which took place from the 6th to the 8th of December in Paris (as a new place for the fair France). Elodie attended it as a visitor, allowing us to meet again our usual partners and to meet future Read more…
Next week we will have the pleasure to attend FOOD INGREDIENTS EUROPE & HEALTH INGREDIENTS EUROPE (FIE/HIE), which will take place in Paris, Porte de Versailles. Food ingredients Europe has been uniting the world’s leading food & beverage suppliers, buyers, R&D experts and production specialists for over 35 years. Originally Read more…
Nous avons eu le plaisir d’être invités par notre distributeur Dutscher, et en particulier par Romain Guegan, à présenter lors de la journée Necker-Imagine organisée à l’INEM (Institut Necker Enfants Malades) le 3 novembre dernier. Elodie a eu l’occasion de présenter aux chercheurs présents notre technologie BIOMIMESYS® pour une culture Read more…
Our project leader Méryl and our CBO Mathieu are currently attending CellME (Cell Manufacturing & Engineering) Forum taking place these days in Berlin, Germany. Méryl had the chance to present his work and the advantages of BIOMIMESYS® for organoid culture earlier today: Please feel free to discuss with them on Read more…
We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…
Dear all, please feel free to contact Elodie who will be in RDV Carnot event in Paris (Espace Champerret, 17e arrondissement) tomorrow and on Thursday. Since HCS Pharma was selected as a laureate amongst innovative start-ups and SMEs for this ecent, she will be the first to pitch at 11:40 Read more…
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the gap between in vivo and in vitro situations by taking into account the extracellular matrix Read more…
Next month, we will have the pleasure to participate in the 23rd EUSAAT (EUropean Society for Alternative to Animal Testing) congress, which will take place in Linz (Austria) on the 26th-28th of September. We have proposed an abstract about how we use 3D in vitro cell culture models for recapitulating Read more…
To treat brain disease is a challeging purpose, since the brain is protected by a barrier made by of tightly-joined endothelial cells of the cerebral microvessels, called the blood–brain barrier (BBB). To improve this route to reach the central nervous system, several strategies have been developed. Among them, researchers try Read more…
We have the pleasure to introduce to you Michelle Haddad, our new CIFRE PhD student, who will work with us and PETALES laboratory (Procédés Et Transformations Alimentaires et Effets sur la Santé, Transformations & Agroressources, ULR 7519, UniLasalle Beauvais) to develop an in vitro intestinal model including microbiota actors. We Read more…
Historically, cancer has been described as originating from modified cells, because of mutations impacting their growth, their differentiation and their way (not) to die. Now, it is widely acknowledged that the microenvironment surrounding these cells is involved in cancer initiation and progression. As explained in the article by Nia Munn Read more…
HCS Pharma était présent au Workshop OoC pour une création et une structuration de la filière, organisé par Biovalley à l’Institut Pierre-Gilles de Gennes (Paris). Nous sommes très heureux d’avoir pu sponsoriser l’événement, mais aussi tout simplement d’y avoir participé – en présentiel – et de pouvoir discuter avec des chercheurs Read more…
